Navigation Links
Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection
Date:4/22/2008

Single, Intramuscular (IM) Dose, Protects up to 75 Percent in Primate Study

PINE BROOK, N.J., April 22 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced pivotal animal efficacy results of Anthim(TM), a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.

Elusys' Anthim is designed as a "just in time" anthrax therapeutic that can be administered by a single, rapid intramuscular injection and has the potential to provide quick protection against the lethal effects of anthrax toxin.

In this study, primates were infected with a highly lethal dose of aerosolized anthrax spores and observed for 60 days. A single IM dose of Anthim provided significant protection (75% survival) when administered at the onset of clinical symptoms of disease (24 hr. post exposure). These results are consistent with a recent rabbit study that showed significant survival of animals treated 24 hours after infection when bacteremia was present.

Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented on the results, "Anthim continues to demonstrate life-saving potential when given in a single, low IM dose after clinical symptoms of infection are present. In earlier animal studies, Anthim provided 100 percent protection when given prior to an anthrax exposure. These results have been consistent across studies whether Anthim was used with or without antibiotics. Our Phase I human safety study demonstrated Anthim is safe and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin."

Dr. Posillico continued, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very excited because the results of our studies show that rapid IM treatment with Anthim has the potential to provide 'instant protective immunity' against the anthrax toxin in a bioterrorism emergency. We believe Anthim represents an extremely important medical countermeasure for the treatment of anthrax and should be added to the National Stockpile."

Currently antibiotics represent the only option for the treatment of anthrax infection. Antibiotics may be effective in killing the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, current antibiotics may not be effective at all against antibiotic resistant strains of anthrax.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. Elusys has been awarded $32 million from the National Institutes of Health and the Department of Defense for development of Anthim, of which $12 million was awarded in September 2007 from the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services for advanced development of Anthim. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs."

About Elusys

Based in Pine Brook, New Jersey, venture-backed Elusys has two corporate partnerships with MedImmune and Pfizer for development of its HP Antibodies targeting select infectious diseases. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit http://www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
2. Special coating greatly improves solar cell performance
3. Method to deliver molecules within embryonic stem cells improves differentiation
4. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
5. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
8. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
9. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... University’s Digital Forensics Club, takes place February 5-6 at the University’s student ... speakers and activities such as workshops and competitions for ample networking, learning ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
Breaking Biology Technology:
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
(Date:1/13/2016)... DUBLIN , January 13, 2016 ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the ... & Identification Market - Estimation & ...
Breaking Biology News(10 mins):